Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Comparison of clinical and pathological characteristics of post-CT immune cell clusters (Y and Z) in BC patients with residual tumor after NCT

From: Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer

   Number = 71  
   Cluster Y Cluster Z P2)
Characteristic   Number % Number %  
Menopausal status Postmenopausal 10 34.5 23 54.8 0.09
Premenopausal 19 65.5 19 45.2  
Tumor type Ductal invasive 27 93.1 40 95.2 0.70
Lobular invasive 2 6.9 2 4.8  
Others 0 0.0 0 0.0  
Grade 3 (pre-CT) Grade 1-2 7 28.0 26 65.0 0.004
Grade 3 18 72.0 14 35.0  
Grade 3 (residual tumor) Grade 1-2 15 51.7 29 74.4 0.053
Grade 3 14 48.3 10 25.6  
HER2 HER2 negative 22 78.6 35 83.3 0.61
HER2 positive 6 21.4 7 16.7  
Hormone-sensitivity Negative 12 42.9 7 16.7 0.016
Positive 16 57.1 35 83.3  
IHC subtype HS 12 42.9 31 73.8 0.033
HS-HER2+ 4 14.3 4 9.5  
HER2+ 2 7.1 3 7.1  
Triple negative 10 35.7 4 9.5  
cN2-3 (pre-CT) cN0-1 19 65.5 32 76.2 0.32
cN2-3 10 34.5 10 23.8  
ypN ypN0 12 41.4 21 50.0 0.47
ypN+ 17 58.6 21 50.0  
ypN2-3 ypN0-1 17 70.8 26 76.5 0.63
ypN2-3 7 29.2 8 23.5  
cT3-4 (pre-CT) cT1-2 12 41.4 20 47.6 0.60
cT3-4 17 58.6 22 52.4  
ypT ypT0/is 0 0.0 0 0.0 0.43
ypT1 10 34.5 9 21.4  
ypT2 12 41.4 19 45.2  
ypT3 4 13.8 11 26.2  
ypT4 3 10.3 2 4.8  
ypTx 0 0.0 1 2.4  
  1. BC, breast cancer; CT, chemotherapy; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry.